Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • JPMorgan Chase & Co. raises Alnylam Pharmaceuticals price target from USD348 to USD475 with overweight rating.
  • Q2 earnings beat estimates by USD0.86 per share, with revenue up 17.3% year-over-year.
  • Stock trades near 12-month high at USD428.14, with average analyst target of USD401.12.

JPMorgan Chase & Co. has increased its price target for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from USD348.00 to USD475.00, according to a report released Wednesday. The firm maintained an “overweight” rating, indicating expectations for further gains from the company’s latest closing price of USD428.14.

Other analysts have also revised their outlooks in recent weeks. UBS Group raised its target from USD403.00 to USD550.00 while keeping a “buy” rating, and BMO Capital Markets increased its projection from USD300.00 to USD360.00 with an “outperform” rating. Wells Fargo & Company moved its target from USD333.00 to USD395.00 with an “equal weight” view, and Wall Street Zen upgraded the stock from “hold” to “buy” in early July.

Institutional investors hold the majority of the stock, with ownership at 92.97%. Notable recent moves include Envestnet Asset Management increasing its position by over 110% in the fourth quarter and FIL Ltd raising its stake by nearly 49%.

Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics, developing treatments for a range of rare and genetic diseases. The company continues to see analyst interest amid its product pipeline progress and revenue growth, though its high leverage and negative margins remain areas of market scrutiny.